VALIDATING AN INDUSTRY-SPONSORED MODEL COMPARING THE COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA

被引：0
|
作者：
Graham, Christopher N. [1 ]
Mauskopf, Josephine [1 ]
Lawson, Anthony H. [2 ]
Ascher-Svanum, Haya [2 ]
Bruhn, David [2 ]
Watson, Peter R. [2 ]
机构：
[1] RTI Hlth Solut Res, Res Triangle Pk, NC USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
SCHIZOPHRENIA RESEARCH | 2010年 / 117卷 / 2-3期
关键词：
D O I：
10.1016/j.schres.2010.02.722
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：398 / 399
页数：2
相关论文
共 50 条
  • [41] Schizophrenia costs and treatment cost-effectiveness
    Knapp, M
    ACTA PSYCHIATRICA SCANDINAVICA, 2000, 102 : 15 - 18
  • [42] A cost-effectiveness analysis model for treatment of chronic schizophrenia in Mexico
    Mould, J
    Contreras-Hernandez, I
    Verduzco, W
    Garduño-Espinosa, J
    VALUE IN HEALTH, 2006, 9 (03) : A67 - A67
  • [43] A cost-effectiveness clinical decision analysis model for treatment of schizophrenia
    Palmer, CS
    Brunner, E
    Ruíz-Flores, LG
    Paez-Agraz, F
    Revicki, DA
    ARCHIVES OF MEDICAL RESEARCH, 2002, 33 (06) : 572 - 580
  • [44] COST-EFFECTIVENESS OF ASENAPINE VERSUS ATYPICAL ANTIPSYCHOTICS USED IN TURKEY IN THE TREATMENT OF BIPOLAR I DISORDER
    Pala, M.
    Ozdemir, S.
    Ozdemir, O.
    VALUE IN HEALTH, 2013, 16 (07) : A548 - A548
  • [45] Cost-effectiveness simulation analysis of schizophrenia at the Instituto Mexicano del Seguro Social: Assessment of typical and atypical antipsychotics
    Mould-Quevedo, Joaquin
    Contreras-Hernandez, Iris
    Verduzco, Wascar
    Manuel Mejia-Arangure, Juan
    Garduno-Espinosa, Juan
    REVISTA DE PSIQUIATRIA Y SALUD MENTAL, 2009, 2 (03): : 108 - 118
  • [46] Cost-effectiveness analysis of paliperidone palmitate compared to other antipsychotics indicated for the treatment of schizophrenia in France
    Druais, S.
    Doutriaux, A.
    Cognet, M.
    Lancon, C.
    Samalin, L.
    Levy, P.
    Godet, A.
    Guillon, P.
    EUROPEAN PSYCHIATRY, 2014, 29 (08) : 653 - 653
  • [47] Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia
    Rosenheck, Robert A.
    Leslie, Douglas L.
    Sindelar, Jody
    Miller, Edward A.
    Lin, Haiqun
    Stroup, T. Scott
    McEvoy, Joseph
    Davis, Sonia M.
    Keefe, Richard S. E.
    Swartz, Marvin
    Perkins, Diana O.
    Hsiao, John K.
    Lieberman, Jeffrey
    AMERICAN JOURNAL OF PSYCHIATRY, 2006, 163 (12): : 2080 - 2089
  • [48] Cost effectiveness of atypical and typical antipsychotics: A compliance Markov model
    Launois, R
    Knapp, M
    van der Schulenburg, MG
    SCHIZOPHRENIA RESEARCH, 1999, 36 (1-3) : 345 - 345
  • [49] Cost-effectiveness of pazopanib: an example of improved transparency and accessibility of industry-sponsored economic evaluations through publication in peer-reviewed journals
    Beca, J.
    Chan, K. K. W.
    CURRENT ONCOLOGY, 2016, 23 (04) : E327 - E329
  • [50] Cost-Effectiveness of Aripiprazole Tablets with Sensor versus Oral Atypical Antipsychotics for the Treatment of Schizophrenia Using a Patient-Level Microsimulation Modeling Approach
    Chopra, Avijeet S.
    Boskovic, Dusica Hadzi
    Kulkarni, Amit
    Cochran, Jeffrey M.
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2023, 15 : 375 - 386
12345